Serum Institute of India wins Facility of the Year Award for Social Impact

SKAN AG is pleased to congratulate its valued client, the Serum Institute of India, for winning the Facility of the Year Award (FOYA) in the Social Impact category. This prestigious award recognises excellence in pharmaceutical manufacturing and highlights the Serum Institute of India’s commitment to social responsibility.

The Serum Institute of India, a global leader in vaccine manufacturing, operates a state-of-the-art, aseptic and sterile production facility. This facility is designed to manufacture a variety of life-saving vaccines such as BCG, HPV, TdaP, monoclonal antibodies/biosimilars, rotavirus vaccines and recombinant BCG vaccines using state-of-the-art manufacturing technologies.

Most notably, the Serum Institute of India converted this facility to produce COVID-19 vaccines in a very short time. In view of the global pandemic, all parties involved were under enormous pressure to speed up vaccine production and meet the demand for life-saving vaccines worldwide.

SKAN AG played an important role in this by supplying three isolator lines for vials together with groninger. Despite the challenging circumstances associated with the pandemic, everyone involved got creative to cross the borders into India. SKAN staff were only allowed to enter the country with special permits as the borders were closed in India as well as in Europe. In addition, seats were booked on return flights that were fully occupied on the way to India and completely empty on the way to Switzerland in order to bring SKAN’s project managers, field engineers and assembly workers safely to their destination.

Winning the Facility of the Year Award in the Social Impact category is a tribute to the Serum Institute of India and its ongoing efforts to improve access to vital vaccines and effect positive change in global health care. SKAN AG looks forward to continuing to work with the Serum Institute of India and other industry leaders to develop innovative solutions for pharmaceutical manufacturing and promote global health.

“We are proud to have been part of this remarkable project and would like to congratulate the Serum Institute of India on this impressive achievement. Despite adverse circumstances, our dedicated employees have done their utmost to support Serum as a reliable partner. We are delighted with the success and the impact this facility will have on vaccine manufacturing.”

Thomas Huber

CEO of the SKAN Group

FacebookLinkedInTwitterWhatsAppCopy Link